Tag: regulatory use of RWE

Real‑World Evidence in Immunotherapy Research

Posted on digi By digi

Real‑World Evidence in Immunotherapy Research Using Real‑World Evidence to Strengthen Immunotherapy Research Introduction: Why Real‑World Evidence Matters for Immunotherapy Immuno‑oncology (IO) therapies such as PD‑1/PD‑L1 and CTLA‑4 inhibitors have reshaped cancer care, but traditional randomized trials can’t answer every question patients, payers, and regulators ask. Real‑world evidence (RWE)—clinical insights derived from routinely collected data like…

Read More “Real‑World Evidence in Immunotherapy Research” »

Immunotherapy Studies, Oncology Clinical Trials

Real-World Evidence (RWE) and Observational Studies: Foundations, Applications, and Best Practices

Posted on digi By digi

Real-World Evidence (RWE) and Observational Studies: Foundations, Applications, and Best Practices Understanding Real-World Evidence (RWE) and Observational Studies: Foundations, Applications, and Best Practices Real-World Evidence (RWE) and Observational Studies are reshaping clinical research and healthcare decision-making by providing insights beyond traditional randomized controlled trials (RCTs). RWE captures outcomes in diverse patient populations under routine clinical…

Read More “Real-World Evidence (RWE) and Observational Studies: Foundations, Applications, and Best Practices” »

Real-World Evidence (RWE) and Observational Studies